Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients who have completed participation in 1 of the core studies in adult rheumatoid arthritis.
You may not be if
Treatment with any investigational agent since the last administration of study drug in the core studies.
Treatment with iv gamma globulin, plasmapheresis, or prosorba column since the last administration of study drug in the core studies.
Treatment with an anti-TNF or anti-IL1 agent, a T-cell co-stimulation modulator, or any biologic since the last administration of study drug in the core studies.
Immunization with a live/attenuated vaccine since the last administration of study drug in the core studies.
Previous treatment with any cell-depleting therapies, including investigational agents.
Parenteral, intramuscular, or intra-articular corticosteroids within 6 weeks prior to baseline in this study.
Clareo Health | An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies
